Literature DB >> 27118199

Risk factors for malignancy in systemic sclerosis patients.

T Kaşifoğlu1, Ş Yaşar Bilge2, F Yıldız3, G Özen4, Y Pehlivan5, N Yılmaz6, F Tarhan7, S Yılmaz8, A Küçük9, H Emmungil10, S S Koca11, M Çınar12, H Direskeneli4, E Erken3, G Can7, M Özmen7, E Gönüllü1, B Kisacik5, K Aksu10, O Karadağ13, N Kasifoglu14, D Arslantas15, F Sahin16, G Keser10, S Yavuz6, M Birlik17, A M Onat5.   

Abstract

Systemic sclerosis (SSc) is an autoimmune connective tissue disease with multisystem involvement. An increased incidence of cancer in SSc patients compared with the general population has been reported in several reports. Our aims in this study were to determine the most common malignancies and to investigate the possible risk factors for the development of malignancy in patients with SSc. Three hundred forty SSc patients from 13 centers were included to the study. Data of the patients were obtained by evaluating their medical records retrospectively. A total of 340 patients with SSc were evaluated. Twenty-five of the patients had 19 different types of malignancy. Bladder cancer was the most common type of cancer with four patients and was followed by breast cancer with three patients, and cervix cancer and ovarian cancer with two patients each. Other types of cancers such as squamous cell skin cancer, adenocancer with an unknown origin, multiple myeloma, chronic myeloid leukemia, papillary thyroid cancer, larynx cancer, non-small cell lung cancer, follicular type non-Hodgkin lymphoma (NHL), endometrium cancer, colon cancer, uterus cancer, neuroendocrine tumor, glioblastoma multiforme, and soft tissue sarcoma were diagnosed in one patient each. The only cancer type that showed an association with cyclophosphamide dose was bladder carcinoma. Other malignancies did not show a correlation with age, sex, smoking, type and duration of the disease, autoantibodies, organ involvement, and dose and duration of cyclophosphamide therapy. Cancer may develop in any organ in patients with SSc. Continuous screening of the patients during a follow-up period is necessary for the early detection of the tumor development.

Entities:  

Keywords:  Cyclophosphamide; Malignancy; Systemic sclerosis

Mesh:

Substances:

Year:  2016        PMID: 27118199     DOI: 10.1007/s10067-016-3288-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

1.  Association of anti-topoisomerase I with cancer.

Authors:  N Rothfield; S Kurtzman; D Vazques-Abad; C Charron; L Daniels; B Greenberg
Journal:  Arthritis Rheum       Date:  1992-06

2.  Spontaneous and clastogen induced chromosomal breakage in scleroderma.

Authors:  D J Wolff; B W Needleman; S S Wasserman; S Schwartz
Journal:  J Rheumatol       Date:  1991-06       Impact factor: 4.666

3.  Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases.

Authors:  P Asten; J Barrett; D Symmons
Journal:  J Rheumatol       Date:  1999-08       Impact factor: 4.666

Review 4.  Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies.

Authors:  Martina Bonifazi; Irene Tramacere; Giovanni Pomponio; Barbara Gabrielli; Enrico V Avvedimento; Carlo La Vecchia; Eva Negri; Armando Gabrielli
Journal:  Rheumatology (Oxford)       Date:  2012-11-22       Impact factor: 7.580

5.  Family studies in scleroderma (systemic sclerosis) demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes.

Authors:  G Rittner; G Schwanitz; M P Baur; C M Black; K I Welsh; P Kühnl; C Rittner
Journal:  Hum Genet       Date:  1988-12       Impact factor: 4.132

Review 6.  Malignancies associated with systemic sclerosis.

Authors:  Éva Szekanecz; Szilvia Szamosi; Ágnes Horváth; Ágnes Németh; Balázs Juhász; János Szántó; Gabriella Szücs; Zoltán Szekanecz
Journal:  Autoimmun Rev       Date:  2012-03-05       Impact factor: 9.754

7.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Authors:  Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

Review 8.  Systemic sclerosis and malignancy: a review of the literature.

Authors:  Marc Wooten
Journal:  South Med J       Date:  2008-01       Impact factor: 0.954

Review 9.  Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies.

Authors:  Akira Onishi; Daisuke Sugiyama; Shunichi Kumagai; Akio Morinobu
Journal:  Arthritis Rheum       Date:  2013-07

10.  Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis.

Authors:  Atsushi Hashimoto; Yoshiyuki Arinuma; Tatsuo Nagai; Sumiaki Tanaka; Toshihiro Matsui; Shigeto Tohma; Hirahito Endo; Shunsei Hirohata
Journal:  Intern Med       Date:  2012-07-01       Impact factor: 1.271

View more
  11 in total

Review 1.  Cancer and Scleroderma.

Authors:  Emma Weeding; Livia Casciola-Rosen; Ami A Shah
Journal:  Rheum Dis Clin North Am       Date:  2020-06-10       Impact factor: 2.670

2.  Mechanistic and clinical insights at the scleroderma-cancer interface.

Authors:  Ami A Shah; Livia Casciola-Rosen
Journal:  J Scleroderma Relat Disord       Date:  2017-10-05

Review 3.  Systemic Sclerosis Association with Malignancy.

Authors:  Gemma Lepri; Martina Catalano; Silvia Bellando-Randone; Serena Pillozzi; Elisa Giommoni; Roberta Giorgione; Cristina Botteri; Marco Matucci-Cerinic; Lorenzo Antonuzzo; Serena Guiducci
Journal:  Clin Rev Allergy Immunol       Date:  2022-09-19       Impact factor: 10.817

4.  Pulmonary metastasis from uterine leiomyosarcoma in a patient with limited cutaneous systemic scleroderma.

Authors:  Shinichiro Okauchi; Hiroko Watanabe; Tomohiro Tamura; Norio Takayashiki; Kesato Iguchi; Hiroaki Satoh; Taiki Sato; Akiko Sakata; Masayuki Noguchi
Journal:  J Gen Fam Med       Date:  2017-05-08

5.  Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature.

Authors:  M Colaci; D Giuggioli; C Vacchi; C Ferri
Journal:  Case Rep Rheumatol       Date:  2017-05-04

Review 6.  Associations between Systemic Sclerosis and Thyroid Diseases.

Authors:  Poupak Fallahi; Ilaria Ruffilli; Dilia Giuggioli; Michele Colaci; Silvia Martina Ferrari; Alessandro Antonelli; Clodoveo Ferri
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-03       Impact factor: 5.555

7.  Development of Two Types of Skin Cancer in a Patient with Systemic Sclerosis: a Case Report and Overview of the Literature.

Authors:  Firdevs Ulutaş; Erdem Çomut; Veli Çobankara
Journal:  Case Rep Oncol Med       Date:  2021-02-26

8.  Advances at the Interface of Cancer and Systemic Sclerosis.

Authors:  Christopher A Mecoli; Antony Rosen; Livia Casciola-Rosen; Ami A Shah
Journal:  J Scleroderma Relat Disord       Date:  2020-03-17

Review 9.  Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors.

Authors:  Alexandre Thibault Jacques Maria; Léo Partouche; Radjiv Goulabchand; Sophie Rivière; Pauline Rozier; Céline Bourgier; Alain Le Quellec; Jacques Morel; Danièle Noël; Philippe Guilpain
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

10.  Lung cancer in patients with and without rheumatoid arthritis: A propensity score-matched survival analysis cohort study.

Authors:  Lei Zhang; Qiliang Zhao; Fan Yuan; Min Liu
Journal:  Thorac Cancer       Date:  2020-03-27       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.